## HRL: Hormel Foods Corporation - XLP: Consumer Defensive

### Executive Summary

No thesis match: MRS_20 2.0% below STRENGTH zone (4.0-10.0%); PEG 3.02 fails VALUE criteria (<1.0). Stock is in no-man's land without clear edge.

- **Horizon:** N/A - no position
- **Risk Profile:** N/A - avoiding
- **Stop Type:** Fixed 2xATR ($22.73)
- **If Wrong:** N/A - wait for clearer setup
- **Invalidation:** MRS_20 falling below -5% or breaking key support

### News

- **Articles:** 9
- **Sentiment:** Neutral (Bullish: 0, Bearish: 0)

**1. Rosen Law Firm Encourages Hormel Foods Corporation Investors to Inquire About Securities Class Action Investigation - HRL**
- Source: WBOY.com | 20251208T202000 | Neutral | Relevance: 99%
-  The Rosen Law Firm is investigating potential securities claims against Hormel Foods Corporation (NYSE: HRL) following allegations of misleading business information. This investigation stems from an October 29, 2025 Wall Street Journal article reporting Hormel's cut forecast due to price pressures, bird flu, and a facility fire, which caused a 9.1% stock drop. Investors who purchased Hormel securities are encouraged to contact the firm for potential compensation in a class action lawsuit.

**2. Hormel Foods seeks to capitalize on protein**
- Source: Baking Business | 20251208T130829 | Neutral | Relevance: 99%
- Hormel Foods is focusing on its legacy as a protein provider, rolling out new products like sandwich-ready bacon and expanding its chicken offerings with brands like Applegate Farms, despite facing significant challenges from surging commodity prices in fiscal 2025. The company's net income for the year decreased, impacted by inflation in raw materials and impairment charges, yet they project growth in net sales and adjusted operating income for fiscal 2026. Hormel is also reshaping its portfolio, recently moving its Justin's business into a strategic partnership and exiting certain private label product lines.

**3. Hormel Foods (NYSE:HRL) Price Target Raised to $28.00**
- Source: MarketBeat | 20251206T155813 | Somewhat-Bullish | Relevance: 98%
-  JPMorgan Chase & Co. has raised its price target for Hormel Foods (NYSE:HRL) from $27.00 to $28.00, maintaining an "overweight" rating and suggesting a 14.5% upside. The consensus rating for HRL is "Hold" with an average price target of $28.86, based on a mix of Buy, Hold, and Sell ratings from various analysts. Hormel recently beat quarterly EPS estimates but slightly missed revenue, and has set FY2026 guidance.

**4. Rosen Law Firm Encourages Hormel Foods Corporation Investors to Inquire About Securities Class Action Investigation - HRL**
- Source: WOWK 13 News | 20251209T012808 | Neutral | Relevance: 97%
-  The Rosen Law Firm is investigating a potential securities class action against Hormel Foods Corporation (NYSE: HRL) after allegations that Hormel may have issued materially misleading business information. This investigation follows a Wall Street Journal article from October 29, 2025, detailing how Hormel cut its forecast due to price pressures, bird flu, and a fire, causing a 9.1% stock drop. Investors who purchased Hormel securities are encouraged to contact the law firm to inquire about potential compensation.

**5. Hormel Foods reports lower earnings despite higher sales as profit drops hit US$56.1M loss**
- Source: Food Business Africa Magazine | 20251208T121508 | Neutral | Relevance: 97%
-  Hormel Foods experienced a significant decline in profitability in fiscal 2025, reporting a net loss of US$56.1 million for the fourth quarter despite slightly higher revenue. The company attributed the profit drop to persistent cost inflation and discrete financial impacts, leading to a full-year net earnings decrease. Looking ahead to 2026, Hormel plans to refine its product mix and improve operational efficiency to reshape its earnings trajectory.

### Analyst Activity

**Target Signal:** NEUTRAL (Raises: 3, Lowers: 1)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-12-05 | Piper Sandler | $26 | $25 | +4% |
| 2025-12-05 | JP Morgan | $28 | $27 | +4% |
| 2025-12-05 | B of A Securiti | $26 | $25 | +4% |
| 2025-11-21 | JP Morgan | $27 | $30 | -10% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-12-05 | Piper Sandler | main | Neutral |
| 2025-12-05 | JP Morgan | main | Overweight |
| 2025-12-05 | B of A Securiti | main | Neutral |
| 2025-11-21 | JP Morgan | main | Overweight |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_BUYING** |
| Buys | 4 ($0.26M) |
| Sells | 0 ($0.00M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 24.9% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 10 / 0 |

**Top Holders:**
- Vanguard Group Inc: 6.8% (+2.0%)
- State Street Corpora: 5.1% (+1.0%)
- Blackrock Inc.: 4.6% (+2.2%)
- Invesco Ltd.: 2.1% (+66.5%)
- Geode Capital Manage: 1.5% (+1.7%)

### Key Risks

1. Valuation risk: PEG 3.0x with declining EPS estimates leaves no margin for error.
2. Long-term trend broken: trading 13.6% below SMA200.
3. Market regime shift could impact momentum names disproportionately.

### Catalysts

- Analyst target momentum: 3 raises (avg +4%) could attract flows.
- AI/machine learning initiatives could drive multiple expansion if executed.
- Momentum building: MRS_20 improving +1.0% over 5 days suggests accumulation.

### Fundamentals

PEG ratio 3.02 signals overvaluation risk, limited margin of safety. Forward P/E 15.2x stretched relative to 8% growth. Balance sheet: strong liquidity (2.5x), low leverage (D/E 0.18). Institutional flow bullish (10 buying vs 0 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $13.1B |
| Beta | 0.33 |
| 52W Range | $21.03 - $33.80 |
| Short Interest | 5.7% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 3.02 |
| Forward P/E | 15.2 |
| Current P/E | 16.4 |
| YoY Growth | 7.5% |
| EPS Direction | FALLING |

### Technicals

MRS_20 strengthening from 1.0% to 2.0% (+1.0% in 5 days), confirming momentum buildup. Below STRENGTH zone by 2.0pp (needs >4.0% for momentum thesis). MRS_5 at 0.3% confirms short-term momentum alignment. AM_20 at 4.1% shows strong absolute momentum above own 20MA. Outperforming sector by 4.1pp, stock-specific strength. Below SMA200 (0.86x), long-term trend not supportive. Elevated volume (1.4x 20MA), institutional activity likely.

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_20 | 2.04% (CS: 71) | Neutral |
| RSI_14 | 60.1 | Neutral |
| MACD Histogram | 0.22 | Bullish |
| vs SMA20 | 1.041x | Above |
| vs SMA50 | 1.028x | Above |
| vs SMA200 | 0.864x | Below |

### Decision

- **Verdict:** AVOID
- **Thesis:** NEUTRAL

### Trade Setup

- **Entry:** $23.85
- **Stop Loss:** $22.73 (4.7% risk)
- **Target:** $24.97 (R:R method)
- **Risk/Reward:** 1.00:1
- **Target Reasoning:** NEUTRAL thesis targets 1.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 446
- **Position Value:** $10,637.10
- **Portfolio %:** 10.64%
- **Risk Dollars:** $500.00
- **Risk Per Trade:** 0.50%
- **Modifiers:** L1 100% | L2 50% | Combined 0.50x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.00x |
| L2 Sector | AVOID (Zone C) | 0.50x |

### Earnings

**Next:** 2026-02-26 (Est: $0.32)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q4 | $0.30 | $0.32 | +6.0% |
| 2025Q3 | $0.41 | $0.35 | -14.5% |
| 2025Q2 | $0.34 | $0.35 | +3.3% |
| 2025Q1 | $0.37 | $0.35 | -6.6% |

---
*RULE-based L3 | 2026-01-06 16:37 | MRS_20*